Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

C0685000

Cefotaxime sodium

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Cefotaxime sodium salt, Cefotaxim sodium salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C16H16N5NaO7S2
Numero CAS:
64485-93-4
Peso molecolare:
477.45
Beilstein:
5711411
Numero MDL:
MFCD00079073
Codice UNSPSC:
41116107
ID PubChem:
329774812
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

cefotaxime

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

[Na+].[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c3csc(N)n3)C([O-])=O

InChI

1S/C16H17N5O7S2.Na/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8;/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26);/q;+1/p-1/b20-9-;/t10-,14-;/m1./s1
AZZMGZXNTDTSME-JUZDKLSSSA-M

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Cefotaxime sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Cefotaxim inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. As a result, bacteria lyse due to cell wall autolytic enzymes.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Broad spectrum third generation cephalosporin antibiotic.
Sales restrictions may apply.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H317,H334

Classi di pericolo

Resp. Sens. 1 - Skin Sens. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Cefoxitin sodium European Pharmacopoeia (EP) Reference Standard

C0688000

Cefoxitin sodium

Cefquinome sulfate VETRANAL®, analytical standard

Supelco

32472

Cefquinome sulfate

Ceftriaxone sodium European Pharmacopoeia (EP) Reference Standard

C0691000

Ceftriaxone sodium

Tazobactam sodium salt β-lactamase inhibitor

Sigma-Aldrich

T2820

Tazobactam sodium salt

Vancomycin hydrochloride European Pharmacopoeia (EP) Reference Standard

V0045000

Vancomycin hydrochloride

Cefoxitin sodium salt

Supelco

C4786

Cefoxitin sodium salt

Ceftazidime

Sigma-Aldrich

CDS020667

Ceftazidime

I Mounchetrou Njoya et al.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 17(34) (2012-09-04)
In April 2012, a cluster of two cases of meningococcal disease caused by rifampicin-resistant C meningococci was reported in the Champagne-Ardenne region, France. The two cases occurred in a student population living in the same town but studying at different
Hetty Blaak et al.
International journal of food microbiology, 168-169, 8-16 (2013-11-12)
The attribution of fresh produce to the overall community-associated exposure of humans to ESBL- or AmpC-producing bacteria is currently unknown. To address this issue, the prevalence of ESBL- and AmpC-producing Enterobacteriaceae on fresh produce produced in the Netherlands was determined.
Lakshmi Chandramohan et al.
Antimicrobial agents and chemotherapy, 56(9), 4765-4770 (2012-06-27)
Very little is known about the prevalence and composition of various types of extended-spectrum β-lactamases (ESBL) in pediatric patients. The aims of this study were the following: (i) to determine the prevalence of ESBLs among Enterobacteriaceae in a tertiary-care pediatric
Yidan Cui et al.
PloS one, 7(11), e48880-e48880 (2012-11-16)
Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae poses serious challenges to clinicians because of its resistance to many classes of antibiotics. The mechanism of synergistic activity of a combination of (-)-epigallocatechin-3-gallate (EGCG) and β-lactam antibiotics cefotaxime was studied on Extended-spectrum β-lactamase producing Escherichia
Katrine Hartung Hansen et al.
Applied and environmental microbiology, 79(3), 794-798 (2012-11-20)
Current knowledge on extended-spectrum beta-lactamases (ESBLs) in animals is based largely on cross-sectional studies and qualitative data. The aim of this longitudinal study was to elucidate carriage proportions and fecal counts of ESBL-producing Escherichia coli in pigs during the production
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.